Format
Items per page
Sort by

Send to:

Choose Destination

Results: 12

Related Articles by Review for PubMed (Select 20169035)

1.

Tenofovir-associated bone density loss.

Grigsby IF, Pham L, Mansky LM, Gopalakrishnan R, Mansky KC.

Ther Clin Risk Manag. 2010 Feb 2;6:41-7.

2.

Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection.

Fung HB, Stone EA, Piacenti FJ.

Clin Ther. 2002 Oct;24(10):1515-48. Review.

PMID:
12462284
3.

Emtricitabine/tenofovir disoproxil fumarate.

[No authors listed]

Drugs R D. 2004;5(3):160-1. Review.

PMID:
15139777
4.

Tenofovir disoproxil fumarate-emtricitabine coformulation for once-daily dual NRTI backbone.

Muñoz de Benito RM, Arribas López JR.

Expert Rev Anti Infect Ther. 2006 Aug;4(4):523-35. Review.

PMID:
17009933
5.

Endocrine complications of human immunodeficiency virus infection: hypogonadism, bone disease and tenofovir-related toxicity.

Cotter AG, Powderly WG.

Best Pract Res Clin Endocrinol Metab. 2011 Jun;25(3):501-15. doi: 10.1016/j.beem.2010.11.003. Review.

PMID:
21663843
6.

The role of HIV and antiretroviral therapy in bone disease.

Gutiérrez F, Masiá M.

AIDS Rev. 2011 Apr-Jun;13(2):109-18. Review.

PMID:
21587342
7.

Tenofovir disoproxil fumarate.

Grim SA, Romanelli F.

Ann Pharmacother. 2003 Jun;37(6):849-59. Review.

PMID:
12773076
8.

Tenofovir: a nucleotide analog for the management of human immunodeficiency virus infection.

Antoniou T, Park-Wyllie LY, Tseng AL.

Pharmacotherapy. 2003 Jan;23(1):29-43. Review.

PMID:
12523458
9.

[Tenofovir: pharmacology and interactions].

Azanza JR, García Quetglas E, Sádaba B, Gómez-Giu A.

Enferm Infecc Microbiol Clin. 2008 Jun;26 Suppl 8:2-6. Review. Spanish.

PMID:
19195431
10.

Tenofovir disoproxil fumarate.

Chapman T, McGavin J, Noble S.

Drugs. 2003;63(15):1597-608. Review.

PMID:
12887265
11.

Osteoporosis and bone health in HIV.

Powderly WG.

Curr HIV/AIDS Rep. 2012 Sep;9(3):218-22. doi: 10.1007/s11904-012-0119-7. Review.

PMID:
22581359
12.

[Renal toxicity in HIV-infected patients receiving HAART including tenofovir].

Madeddu G, Quirino T, Carradori S, Ricci E, Grosso C, Penco G, De Socio G, Rossella E, Palvarini L, Marconi P, Melzi S, Mura MS, Bonfanti P; Gruppo CISAI.

Infez Med. 2006 Sep;14(3):125-34. Review. Italian.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk